A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

For weight loss, weight management, and overall wellness, focus on eating healthy foods, like high-protein meals, legumes, whole fruits, low-starch veggies, low-fat dairy, and whole grains. A bland ...

The global glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 19.70 billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity across the globe.

Poland's military purchases from South Korea are an example for other U.S. allies while also pointing to the need for European defense expansion.

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes ...

A study explored glucagon metabolism in humans with and without Type 1 diabetes using stable glucagon tracers. Findings reveal significant differences in splanchnic and leg glucagon metabolism.

By adding glucagon to the mix, GLP-1 and GIP end up neutralizing its glucose-enhancing effect, leaving the remaining functionalities of all three hormones working together to enhance weight loss.

Evidence suggests that incretin-based dual agonist pharmacotherapy is helpful in persons with obesity. Mazdutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, may have efficacy in ...

Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said ...

The candidate at the center of the deal, dubbed UBT251, is a triple agonist for GLP-1, GIP and glucagon.